AstraZeneca PLC
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Tagrisso (osimertinib) — Worldwide product sales by Year
Tagrisso (osimertinib) — Worldwide product sales ($M) ($M)
AstraZeneca Tagrisso (osimertinib) — Worldwide product sales: $7,254M in FY2025, up 10.2% from a year earlier. That is the highest of the 10 years on record here.
Where the FY2025 figure comes from
“|| Tagrisso | 7,254 | 10 | 10 | 3,064 | 11 | 1,971 | 12 | 14 | 1,423 | 9 | 6 | 796 | 5 | 5”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K Quarterly & Form 20-F Product Sales by Medicine & Region Tables.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Tagrisso (osimertinib) — Worldwide product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 7,254 | +10.2% | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 6,580 | +13.5% | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | 5,799 | +6.5% | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | 5,444 | +8.6% | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | 5,015 | +15.9% | Form 6-K FY2021Q4 Earnings Release ↗ |
| FY2020 | Dec 31, 2020 | 4,328 | +35.7% | Form 6-K FY2020Q4 Earnings Release ↗ |
| FY2019 | Dec 31, 2019 | 3,189 | +71.5% | Form 20-F (filed 2020-03-03) ↗ |
| FY2018 | Dec 31, 2018 | 1,860 | +94.8% | Form 20-F (filed 2019-03-05) ↗ |
| FY2017 | Dec 31, 2017 | 955 | +125.8% | Form 20-F (filed 2019-03-05) ↗ |
| FY2016 | Dec 31, 2016 | 423 | – | Form 20-F (filed 2019-03-05) ↗ |
Breakdown
What makes up tagrisso (osimertinib) — Worldwide product sales
- Tagrisso (osimertinib) — Worldwide YoY actual (%)10.0% · FY2025
- Tagrisso (osimertinib) — Worldwide YoY CER (%)10.0% · FY2025
- Tagrisso (osimertinib) — US product sales ($M)3,064 · FY2025
- Tagrisso (osimertinib) — Emerging Markets product sales ($M)1,971 · FY2025
- Tagrisso (osimertinib) — Europe product sales ($M)1,423 · FY2025
- Tagrisso (osimertinib) — Established RoW product sales ($M)796 · FY2025
Cite this data
StockData. (2026). AstraZeneca Tagrisso (osimertinib) — Worldwide product sales ($M), annual FY2016–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-tagrisso-world
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.